Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers.
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics
- Sponsors IRIS
- 01 Mar 2012 Status changed from recruiting to completed as reported by ISRCTN.
- 12 May 2011 Planned end date changed from 30 Sep 2011 to 29 Feb 2012 as reported by ISRCTN.
- 03 Dec 2010 Planned end date (30 Sep 2011) added as reported by ISRCTN: Current Controlled Trials record.